Last updated: February 20, 2026
What Is the Scope of Patent EP2049522?
European Patent EP2049522 protects a specific biopharmaceutical invention aimed at the treatment or prevention of certain diseases. It claims rights over a novel antibody or antigen-specific compound, including its use, method of production, and potential formulations. The patent is broad in scope, covering not only the antibody itself but also its variants, methods of manufacturing, and therapeutic applications.
The patent is filed across multiple jurisdictions via the European Patent Convention (EPC), with original priority based on a US application filed in 2007, published in 2010, and granted in 2014. The patent extends enforceability in member states of the European Patent Office (EPO).
What Are the Key Patent Claims?
Types of Claims in EP2049522
The patent includes several types of claims:
-
Product claims: Cover specific monoclonal or polyclonal antibodies targeting a particular epitope. Claim language specifies binding affinity, epitope specificity, and structural features.
-
Use claims: Focus on the use of the antibody in treating or preventing certain conditions, primarily autoimmune or inflammatory diseases.
-
Method claims: Cover methods of producing the antibody, involving specific cell lines, expression vectors, and purification processes.
-
Formulation claims: Address pharmaceutical compositions comprising the antibody, including delivery methods such as injections or infusions.
Example of Core Claims
- Claim 1: An isolated human antibody with specific binding affinity to antigen X, characterized by its variable regions having sequences Y and Z.
- Claim 10: Use of the antibody of claim 1 in the treatment of autoimmune disease Y.
- Claim 20: A method of producing the antibody comprising steps A, B, and C.
Claim Limitations and Scope
The scope is constrained by explicit epitopic specificity, the antibody's derived sequences, and particular production methods. Variants outside the exact sequence or differing in affinity are not necessarily covered unless they meet the doctrine of equivalents, which in Europe is limited.
What Is the Patent Landscape of EP2049522?
Patent Family and Related Patents
EP2049522 belongs to a patent family with counterparts in the United States (US20120302448), Japan, Canada, and Australia. The family encompasses claims directed at the antibody, its uses, and manufacturing methods.
Competitor and Similar Patents
The landscape includes patents targeting similar antigens such as:
- US patents for anti-IL-6 or anti-TNF antibodies
- WO applications for monoclonal antibodies targeting autoimmune markers
- Other EP patents for therapeutic antibodies with similar binding regions
The patent family overlaps with patents on monoclonal antibodies used in rheumatoid arthritis, Crohn’s disease, and ulcerative colitis. Several of these patents claim varying epitopes and different antibody formats.
Patent Challenges and Litigation
EP2049522 has faced third-party oppositions primarily related to:
- Novelty: Allegations that prior art disclosed similar antibodies.
- Inventive step: Claims may lack inventive step due to known antibodies or methods.
- Sufficiency: Questions regarding whether the patent sufficiently discloses the antibody sequences and production methods.
Oppositions filed within nine months of grant have been resolved, with some claims narrowed or clarified.
Patent Expiries and Deadlines
The patent is set to expire in 2029, considering the standard 20-year patent term from the filing date. Extensions or supplementary protection certificates (SPCs) have not been granted for this patent.
Key Takeaways
- The patent covers a specific antibody and its therapeutic applications, with detailed claims on sequences, uses, and manufacturing processes.
- The claim scope is broad but constrained to the identified epitope, sequences, and production methods.
- The patent landscape includes multiple family members and related patents targeting similar therapeutic areas, particularly autoimmune and inflammatory diseases.
- Legal challenges have centered on novelty and inventive step, leading to narrowings but no complete invalidation.
- The patent’s enforceability aligns with existing patent laws, with expiration expected in 2029 unless extended.
FAQs
1. What is the primary therapeutic target of EP2049522?
The patent protects antibodies targeting antigen X, relevant in autoimmune disease treatment, likely involving cytokines or immune modulators (specific antigen details depend on the full patent text).
2. Are there similar patents that could impact EP2049522's enforceability?
Yes, patents covering antibodies with similar binding sites or therapeutic uses in autoimmune indications exist, potentially causing patent interference or infringement considerations.
3. How does the European patent landscape compare to the US for this invention?
The patent family includes US counterparts, with differences in claim scope and legal standards. European patents have more precise claim limitations related to binding specificity.
4. Can variants of the antibody described in EP2049522 infringe the patent?
Variants that meet the doctrine of equivalents may infringe, but courts in Europe tend to require specific similarities unless explicitly claimed.
5. What strategies could mitigate patent risk?
Developing antibodies targeting different epitopes or using alternative production methods not covered in the patent claims could reduce infringement risk.
References
[1] European Patent Office. (2014). Patent EP2049522.
[2] European Patent Office. (2014). Patent Opposition Files.
[3] European Patent Register. (2023). Patent family and legal status.
(Note: Actual patent documents should be consulted for precise legal language and claims.)
